Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer

Phase 3setidegrasibPositive

AI Analysis

Summary

Astellas dosed the first patient in a Phase 3 study evaluating setidegrasib, a KRAS G12D-targeted protein degrader, versus docetaxel in previously treated patients with advanced NSCLC. This marks the second Phase 3 study of setidegrasib initiated within six months.

Clinical Trial Data

Phase

Phase 3

Outcome Details

First patient dosed in Phase 3 study

Importance:6/10

Sentiment:

0.60

setidegrasibKRAS G12DNSCLCPhase 3protein degraderclinical trial

Related Companies

$ALPMY

Read the original article

Published by PR Newswire Biotech on September 23, 2026 11:30 PM

Read Original